📊 BBNX Key Takeaways
Is Beta Bionics, Inc. (BBNX) a Good Investment?
Beta Bionics demonstrates strong revenue growth of 53.9% YoY and an impressive 55.4% gross margin, indicating solid product-market demand and manufacturing efficiency. However, the company is deeply unprofitable with -73.0% net margin, burning significant cash (-$56.2M FCF annually), and lacks a clear path to profitability despite substantial assets. With only $31.6M in cash against annual cash burn of $50.9M from operations, the runway appears limited absent near-term operational improvements or capital infusion.
Beta Bionics is showing strong top-line momentum, with revenue up 53.9% year over year and a solid 55.4% gross margin, indicating meaningful commercial traction and a viable product economics base. However, the business remains deeply unprofitable, with operating and free cash flow losses still very large relative to revenue, so the fundamental story depends on whether growth can translate into materially improved operating leverage.
Why Buy Beta Bionics, Inc. Stock? BBNX Key Strengths
- Robust revenue growth of 53.9% YoY indicating strong market demand and product traction
- Healthy gross margin of 55.4% demonstrates effective cost of goods control and pricing power
- Strong balance sheet with minimal debt (Debt/Equity 0.00x) and $287.6M in stockholders equity providing flexibility
- Excellent liquidity position with 8.66x current ratio provides near-term operational cushion
- Revenue growth is strong at 53.9% year over year, indicating expanding adoption
- Gross margin of 55.4% suggests the core product economics are reasonably attractive
- Balance sheet is strong with high liquidity, substantial equity capital, and no meaningful debt burden
BBNX Stock Risks: Beta Bionics, Inc. Investment Risks
- Severe operating losses of -$71.7M with -71.5% operating margin indicate inability to scale profitably despite revenue growth
- Significant cash burn of -$56.2M in free cash flow annually; at current burn rate, $31.6M cash reserves provide ~7 months of runway
- Net income deteriorated to -$73.2M loss despite revenue growth, suggesting operating leverage is moving in wrong direction
- High insider trading activity (17 Form 4 filings in 90 days) may indicate uncertainty among management
- Operating margin of -71.5% shows the company is still far from sustainable profitability
- Free cash flow of -$56.22M and negative operating cash flow indicate continued cash burn
- Returns on equity and assets are deeply negative, suggesting current growth is not yet generating efficient earnings power
Key Metrics to Watch
- Path to operating profitability - critical to monitor when operating margin approaches 0% or turns positive
- Cash burn rate and runway - essential to track quarterly operating cash flow to assess sustainability of current operations
- Operating leverage - watch gross profit growth relative to opex increases to identify when company reaches inflection point
- Operating margin trajectory - improvement toward industry benchmarks (>15-20%) would signal operational maturation
- Operating loss and free cash flow burn relative to revenue growth
- Gross margin stability and improvement in operating margin as scale increases
Beta Bionics, Inc. (BBNX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 8.66x current ratio provides a solid financial cushion.
BBNX Profit Margin, ROE & Profitability Analysis
BBNX vs Healthcare Sector: How Beta Bionics, Inc. Compares
How Beta Bionics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Beta Bionics, Inc. Stock Overvalued? BBNX Valuation Analysis 2026
Based on fundamental analysis, Beta Bionics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Beta Bionics, Inc. Balance Sheet: BBNX Debt, Cash & Liquidity
BBNX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Beta Bionics, Inc.'s revenue has grown significantly by 54% over the 5-year period, indicating strong business expansion. The most recent EPS of $-8.60 indicates the company is currently unprofitable.
BBNX Revenue Growth, EPS Growth & YoY Performance
BBNX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $16.7M | -$9.7M | $-0.33 |
| Q2 2025 | $15.0M | -$14.5M | $-0.39 |
| Q1 2025 | $12.9M | -$12.4M | $-0.93 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Beta Bionics, Inc. Dividends, Buybacks & Capital Allocation
BBNX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Beta Bionics, Inc. (CIK: 0001674632)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 10, 2026 | DEF 14A | bbnx-20260408.htm | View → |
| Mar 16, 2026 | 4 | xslF345X05/form4-03162026_070303.xml | View → |
| Mar 16, 2026 | 4 | xslF345X05/form4-03162026_070301.xml | View → |
| Mar 5, 2026 | 4 | xslF345X05/form4-03062026_120301.xml | View → |
| Mar 3, 2026 | 4 | xslF345X05/form4-03032026_060310.xml | View → |
❓ Frequently Asked Questions about BBNX
What is the AI rating for BBNX?
Beta Bionics, Inc. (BBNX) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BBNX's key strengths?
Claude: Robust revenue growth of 53.9% YoY indicating strong market demand and product traction. Healthy gross margin of 55.4% demonstrates effective cost of goods control and pricing power. ChatGPT: Revenue growth is strong at 53.9% year over year, indicating expanding adoption. Gross margin of 55.4% suggests the core product economics are reasonably attractive.
What are the risks of investing in BBNX?
Claude: Severe operating losses of -$71.7M with -71.5% operating margin indicate inability to scale profitably despite revenue growth. Significant cash burn of -$56.2M in free cash flow annually; at current burn rate, $31.6M cash reserves provide ~7 months of runway. ChatGPT: Operating margin of -71.5% shows the company is still far from sustainable profitability. Free cash flow of -$56.22M and negative operating cash flow indicate continued cash burn.
What is BBNX's revenue and growth?
Beta Bionics, Inc. reported revenue of $100.3M.
Does BBNX pay dividends?
Beta Bionics, Inc. does not currently pay dividends.
Where can I find BBNX SEC filings?
Official SEC filings for Beta Bionics, Inc. (CIK: 0001674632) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BBNX's EPS?
Beta Bionics, Inc. has a diluted EPS of $-1.81.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BBNX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Beta Bionics, Inc. has a SELL rating with 80% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BBNX stock overvalued or undervalued?
Valuation metrics for BBNX: ROE of -25.5% (sector avg: 15%), net margin of -73.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BBNX stock in 2026?
Our dual AI analysis gives Beta Bionics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BBNX's free cash flow?
Beta Bionics, Inc.'s operating cash flow is $-50.9M, with capital expenditures of $5.3M. FCF margin is -56.1%.
How does BBNX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -73.0% (avg: 12%), ROE -25.5% (avg: 15%), current ratio 8.66 (avg: 2).